Read the full stored bill text
- 2025
69th Legislature 2025 HB0371.2
- 1 - Authorized Print Version – HB 371
1 HOUSE BILL NO. 371
2 INTRODUCED BY G. KMETZ, L. SCHUBERT, K. LOVE, T. SHARP, R. GREGG, E. TILLEMAN, T.
3 MANZELLA, D. EMRICH, S. GIST, R. MARSHALL, J. SCHILLINGER, L. DEMING, S. MANESS
4
5 A BILL FOR AN ACT ENTITLED: “AN ACT PROHIBITING THE ADMINISTRATION OF GENE-BASED
6 VACCINES FOR INFECTIOUS DISEASES INTO HUMANS IN THE STATE OF MONTANA; PROVIDING A
7 DEFINITION; AND PROVIDING A PENALTY.”
8
9 WHEREAS, the mRNA vaccines have caused enormous numbers of deaths, disabilities, and serious
10 adverse events; and
11 WHEREAS, no long-term studies have been completed regarding fertility, teratogenicity, mutagenicity,
12 or oncogenicity; and
13 WHEREAS, recipients are not given informed consent; and
14 WHEREAS, the mRNA vaccines may integrate into the human genome and be passed onto the next
15 generation; and
16 WHEREAS, the mRNA vaccines are contaminated with DNA, metallic particles, and other unknown
17 nanoparticles; and
18 WHEREAS, the mRNA vaccines may shed to others and cause side effects or harm.
19
20 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
21
22 NEW SECTION. Section 1. Administration of gene-based vaccines FOR INFECTIOUS DISEASES. (1)
23 A person may not provide or administer a gene-based vaccine FOR INFECTIOUS DISEASES to a human within the
24 state.
25 (2) A person who violates this section is guilty of a misdemeanor and is subject to a $500 fine for
26 each incident.
27 (3) The appropriate licensure board within the Montana department of labor and industry shall
28 review the license of a person who is licensed under Title 37 and who violates this section.
- 2025
69th Legislature 2025 HB0371.2
- 2 - Authorized Print Version – HB 371
1 (4) (A) For the purposes of this section, "gene-based vaccine FOR INFECTIOUS DISEASES" means a
2 vaccine FOR INFECTIOUS DISEASES developed using messenger ribonucleic acid (mRNA) technology, modified
3 messenger ribonucleic acid technology, self-amplifying messenger ribonucleic acid technology, or
4 deoxyribonucleic acid technology.
5 (B) THE TERM DOES NOT INCLUDE GENE THERAPY PRODUCTS USED TO TREAT CANCER OR GENETIC
6DISORDERS.
7
8 NEW SECTION. Section 2. Codification instruction. [Section 1] is intended to be codified as an
9 integral part of Title 45, chapter 5, and the provisions of Title 45, chapter 5, apply to [section 1].
10 - END -